Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer-Reference-Cited by-同舟云学术

Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer

Published:2022-08-10 Issue:8 Volume:5 Page:e2225485
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Hu Xin¹,Walker Mark S.²,Stepanski Edward²,Kaplan Cameron M.³,Martin Michelle Y.⁴,Vidal Gregory A.⁵⁶,Schwartzberg Lee S.⁷,Graetz Ilana¹

Affiliation:

1. Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia

2. ConcertAI, Boston, Massachusetts

3. Gehr Family Center for Health Systems Science and Innovation, Keck School of Medicine, University of Southern California, Los Angeles

4. Center for Innovation in Health Equity Research, Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis

5. West Cancer Center and Research Institute, Germantown, Tennessee

6. Division of Hematology and Oncology, College of Medicine, University of Tennessee Health Science Center, Memphis

7. Renown Institute for Cancer, Reno, Nevada

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2794991/hu_2022_oi_220713_1659120994.05812.pdf

Reference54 articles.

1. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.;Tjan-Heijnen;Lancet Oncol,2017

2. Extending aromatase-inhibitor adjuvant therapy to 10 years.;Goss;N Engl J Med,2016